Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting

Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting

Abstract Background Long-term prophylactic therapy is considered the standard of care for hemophilia A patients. This study models the long-term clinical and cost outcomes of two factor VIII (FVIII) products using a pharmacokinetic (PK) simulation model in a Chinese population. Methods Head-to-head...

Full description

Bibliographic Details
Main Authors: Rong Chen, Dmitry Gultyaev, Johanna Lister, Rong Han, Nan Hu, Jean Malacan, Alexander Solms, Parth Vashi, Jamie O’Hara, Shanlian Hu
Format: Article
Language:English
Published: BMC 2022-08-01
Series:BMC Medical Research Methodology
Subjects:
Hemophilia A
Factor VIII products
Pharmacokinetic
China
Economic model
BAY 81–8973
Online Access:https://doi.org/10.1186/s12874-022-01659-w

Internet

https://doi.org/10.1186/s12874-022-01659-w

Similar Items